Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2021-12-01 00:00:00 ET · period of report 2021-11-29 · accession 0001415889-21-005622 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-01 | 2021-11-29 | OLMA | Harmon Cyrus | CTO, Dir | S - Sale | $24.76 | -400 | 1.05M | -0.0% | -$9,904 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-29 | S | D | 400 | $24.76 | 1,051,146 | D | — | — | (F2) The weighted average sale price for the transaction reported was $24.76, and the range of prices were between $24.75 and $24.80. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |